Considering the up-regulated levels of HPV16-specific CD8+ T cells in the TME, we postulated that a combined approach integrating MHC-I‒E6‒mEry with PD-1/PD-L1 checkpoint blockade might enhance anti-tumor effects. Here, CD8A is linked to neoplasm.